Epigenetics of brain disorders

Handbook of Epigenetics

Volumn , Issue , 2011, Pages 553-567

  Gräff, Johannes ^a   Franklin, Tamara B ^a   Mansuy, Isabelle M ^a  

^a University of Zurich Brain Research Institute   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84555184155     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-375709-8.00034-4     Document Type: Chapter

References (108)

1. Epigenetic mechanisms of gene regulation 1996, Cold Spring Harbour Laboratory Press, Woodbury. V.E.A. Russo, R.A. Martienssen, A.D. Riggs (Eds.).
2. Bird A Perceptions of epigenetics. Nature 2007, 447:396-398.
3. Jaenisch R, Bird A Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003, 33:245-254.
4. Levenson JM, Sweatt JD Epigenetic mechanisms in memory formation. Nat Rev Neurosci 2005, 6:108-118.
5. Bird A DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16:6-21.
6. Klose RJ, Bird AP Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006, 31:89-97.
7. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006, 66:11954-11966.
8. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007, 39:457-466.
9. Tweedie-Cullen RY, Reck JM, Mansuy IM Comprehensive mapping of post-translational modifications on synaptic, nuclear, and histone proteins in the adult mouse brain. J Proteome Res 2009, 8:4966-4982.
10. Keppler BR, Archer TK Chromatin-modifying enzymes as therapeutic targets-Part2. Expert Opin Ther Targets 2008, 12:1457-1467.
11. Keppler BR, Archer TK Chromatin-modifying enzymes as therapeutic targets-Part1. Expert Opin Ther Targets 2008, 12:1301-1312.
12. Li B, Carey M, Workman JL The role of chromatin during transcription. Cell 2007, 128:707-719.
13. Klose RJ, Zhang Y Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 2007, 8:307-318.
14. Peters AH, Schubeler D Methylation of histones: playing memory with DNA. Curr Opin Cell Biol 2005, 17:230-238.
15. Shilatifard A Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem 2006, 75:243-269.
16. He H, Lehming N Global effects of histone modifications. Brief Funct Genomic Proteomic 2003, 2:234-243.
17. Nathan D, Ingvarsdottir K, Sterner DE, Bylebyl GR, Dokmanovic M, Dorsey LA, et al. Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications. Genes Dev 2006, 20:966-976.
18. Shiio Y, Eisenman RN Histone sumoylation is associated with transcriptional repression. Proc Natl Acad Sci USA 2003, 100:13225-13230.
19. Koshibu K, GräffJ, Beullens M, Heitz FD, Berchtold D, Russig H, et al. Protein phosphatase 1 regulates the histone code for long-term memory. J Neurosci 2009, 29:13079-13089.
20. Jenuwein T, Allis CD Translating the histone code. Science 2001, 293:1074-1080.
21. Turner BM Cellular memory and the histone code. Cell 2002, 111:285-291.
22. GräffJ, Mansuy IM Epigenetic codes in cognition and behavior. Behav Brain Res 2008, 192:70-87.
23. GräffJ, Mansuy IM Epigenetic dysregulation in cognitive disorders. Eur J Neurosci 2009, 30:1-8.
24. Urdinguio RG, Sanchez-Mut JV, Esteller M Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009, 8:1056-1072.
25. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999, 23:185-188.
26. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
27. Chen RZ, Akbarian S, Tudor M, Jaenisch R Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001, 27:327-331.
28. Guy J, Hendrich B, Holmes M, Martin JE, Bird A A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001, 27:322-326.
29. Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet 2004, 13:2679-2689.
30. Tao J, Hu K, Chang Q, Wu H, Sherman NE, Martinowich K, et al. Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function. Proc Natl Acad Sci USA 2009, 106:4882-4887.
31. Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, Jaenisch R, Greenberg ME Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003, 302:885-889.
32. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003, 302:890-893.
33. Zhou Z, Hong EJ, Cohen S, Zhao WN, Ho HY, Schmidt L, et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006, 52:255-269.
34. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 2006, 49:341-348.
35. Larimore JL, Chapleau CA, Kudo S, Theibert A, Percy AK, Pozzo-Miller L Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations. Neurobiol Dis 2009, 34:199-211.
36. Sun YE, Wu H The ups and downs of BDNF in Rett syndrome. Neuron 2006, 49:321-323.
37. Maezawa I, Swanberg S, Harvey D, LaSalle JM, Jin LW Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci 2009, 29:5051-5061.
38. Urdinguio RG, Lopez-Serra L, Lopez-Nieva P, Alaminos M, Diaz-Uriarte R, Fernandez AF, Esteller M Mecp2-null mice provide new neuronal targets for Rett syndrome. PLoS ONE 2008, 3:e3669.
39. Smrt RD, Eaves-Egenes J, Barkho BZ, Santistevan NJ, Zhao C, Aimone JB, et al. Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiol Dis 2007, 27:77-89.
40. Kouzarides T Chromatin modifications and their function. Cell 2007, 128:693-705.
41. Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, Noebels J, et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 2002, 35:243-254.
42. Monteggia LM, Kavalali ET Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. Biol Psychiatry 2009, 65:204-210.
43. Deutsch SI, Rosse RB, Mastropaolo J, Long KD, Gaskins BL Epigenetic therapeutic strategies for the treatment of neuropsychiatric disorders: ready for prime time?. Clin Neuropharmacol 2008, 31:104-119.
44. Cummings JL Alzheimer's disease. N Engl J Med 2004, 351:56-67.
45. LaFerla FM, Kitazawa M Antipodal effects of p25 on synaptic plasticity, learning, and memory--too much of a good thing is bad. Neuron 2005, 48:711-712.
46. Cao X, Sudhof TC A transcriptionally (correction of transcriptively) active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001, 293:115-120.
47. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 2003, 114:635-645.
48. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. Embo J 2007, 26:3169-3179.
49. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, Boutillier AL Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 2003, 22:6537-6549.
50. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004, 42:23-36.
51. Fischer A, Sananbenesi F, Wang XY, Dobbin M, Tsai LH Recovery of learning and memory is associated with chromatin remodeling. Nature 2007, 447:178-182.
52. Kazantsev AG, Thompson LM Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008, 7:854-868.
53. Scarpa S, Fuso A, D'Anselmi F, Cavallaro RA Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease?. FEBS Lett 2003, 541:145-148.
54. Scarpa S, Cavallaro RA, D'Anselmi F, Fuso A Gene silencing through methylation: an epigenetic intervention on Alzheimer disease. J Alzheimers Dis 2006, 9:407-414.
55. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 2008, 28:3-9.
56. Wang SC, Oelze B, Schumacher A Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS ONE 2008, 3:e2698.
57. Berton O, Nestler EJ New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
58. Tsankova N, Renthal W, Kumar A, Nestler EJ Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007, 8:355-367.
59. Chen AC, Shin KH, Duman RS, Sanacora G ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment. J ECT 2001, 17:27-32.
60. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003, 54:703-709.
61. Altar CA, Laeng P, Jurata LW, Brockman JA, Lemire A, Bullard J, et al. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 2004, 24:2667-2677.
62. Tsankova NM, Kumar A, Nestler EJ Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. J Neurosci 2004, 24:5603-5610.
63. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-525.
64. Wilkinson MB, Xiao G, Kumar A, LaPlant Q, Renthal W, Sikder D, et al. Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models. J Neurosci 2009, 29:7820-7832.
65. Renthal W, Maze I, Krishnan V, Covington HE, Xiao G, Kumar A, et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007, 56:517-529.
66. Cassel S, Carouge D, Gensburger C, Anglard P, Burgun C, Dietrich JB, Aunis D, et al. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol Pharmacol 2006, 70:487-492.
67. Poulter MO, Du L, Weaver IC, Palkovits M, Faludi G, Merali Z, et al. GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. Biol Psychiatry 2008, 64:645-652.
68. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993, 50:85-94.
69. Singh SM, Murphy B, O'Reilly R Epigenetic contributors to the discordance of monozygotic twins. Clin Genet 2002, 62:97-103.
70. Costa E, Chen Y, Dong E, Grayson DR, Kundakovic M, Maloku E, et al. GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. Expert Rev Neurother 2009, 9:87-98.
71. Fatemi SH Reelin glycoprotein: structure, biology and roles in health and disease. Mol Psychiatry 2005, 10:251-257.
72. Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 1998, 95:15718-15723.
73. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000, 57:1061-1069.
74. Chen Y, Sharma RP, Costa RH, Costa E, Grayson DR On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res 2002, 30:2930-2939.
75. Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I, Tueting P, et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci USA 2002, 99:17095-17100.
76. Dong E, Agis-Balboa RC, Simonini MV, Grayson DR, Costa E, Guidotti A Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc Natl Acad Sci USA 2005, 102:12578-12583.
77. Huang HS, Akbarian S GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS ONE 2007, 2:e809.
78. Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, Yoshikawa T, et al. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci 2005, 25:5376-5381.
79. Veldic M, Guidotti A, Maloku E, Davis JM, Costa E In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci USA 2005, 102:2152-2157.
80. Guidotti A, Ruzicka W, Grayson DR, Veldic M, Pinna G, Davis JM, Costa E S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. Neuroreport 2007, 18:57-60.
81. Antun FT, Burnett GB, Cooper AJ, Daly RJ, Smythies JR, Zealley AK The effects of L-methionine (without MAOI) in schizophrenia. J Psychiatr Res 1971, 8:63-71.
82. Costa E, Chen Y, Davis J, Dong E, Noh JS, Tremolizzo L, et al. REELIN and schizophrenia: a disease at the interface of the genome and the epigenome. Mol Interv 2002, 2:47-57.
83. van Vliet J, Oates NA, Whitelaw E Epigenetic mechanisms in the context of complex diseases. Cell Mol Life Sci 2007, 64:1531-1538.
84. Abdolmaleky HM, Cheng KH, Faraone SV, Wilcox M, Glatt SJ, Gao F, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 2006, 15:3132-3145.
85. Petronis A, Gottesman II, Kan P, Kennedy JL, Basile VS, Paterson AD, et al. Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance?. Schizophr Bull 2003, 29:169-178.
86. Gottlicher M Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 2004, 83(Suppl 1):S91-S92.
87. Carew JS, Giles FJ, Nawrocki ST Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008, 269:7-17.
88. Kundakovic M, Chen Y, Guidotti A, Grayson DR The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol Pharmacol 2009, 75:342-354.
89. Tremolizzo L, Doueiri MS, Dong E, Grayson DR, Davis J, Pinna G, et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 2005, 57:500-509.
90. Li J, Guo Y, Schroeder FA, Youngs RM, Schmidt TW, Ferris C, et al. Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. J Neurochem 2004, 90:1117-1131.
91. Champagne FA, Francis DD, Mar A, Meaney MJ Variations in maternal care in the rat as a mediating influence for the effects of environment on development. Physiol Behav 2003, 79:359-371.
92. Meaney MJ Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Annu Rev Neurosci 2001, 24:1161-1192.
93. Seckl JR, Meaney MJ Glucocorticoid "programming" and PTSD risk. Ann N Y Acad Sci 2006, 1071:351-378.
94. Liu D, Diorio J, Tannenbaum B, Caldji C, Francis D, Freedman A, et al. Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. Science 1997, 277:1659-1662.
95. Weaver ICG, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004, 7:847-854.
96. Weaver IC, D'Alessio AC, Brown SE, Hellstrom IC, Dymov S, Sharma S, et al. The transcription factor nerve growth factor-inducible protein a mediates epigenetic programming: altering epigenetic marks by immediate-early genes. J Neurosci 2007, 27:1756-1768.
97. Weaver ICG, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ, et al. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci 2005, 25:11045-11054.
98. Weaver IC, Meaney MJ, Szyf M Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc Natl Acad Sci USA 2006, 103:3480-3485.
99. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, Turecki G, Meaney MJ Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009, 12:342-348.
100. Francis D, Diorio J, Liu D, Meaney MJ Nongenomic transmission across generations of maternal behavior and stress responses in the rat. Science 1999, 286:1155-1158.
101. Murgatroyd C, Patchev AV, Wu Y, Micale V, Bockmuhl Y, Fischer D, et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci 2009, 12:1559-1566.
102. Franklin T, Russig H, Weiss IC, GräffJ, Linder N, Michalon A, et al. Non-genomic transmission of the impact of early stress across generations. Biol Psych 2010, (in press).
103. Abel T, Zukin RS Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol 2008, 8:57-64.
104. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009, 459:55-60.
105. Martienssen RA, Zaratiegui M, Goto DB RNA interference and heterochromatin in the fission yeast Schizosaccharomyces pombe. Trends Genet 2005, 21:450-456.
106. Chow JC, Yen Z, Ziesche SM, Brown CJ Silencing of the mammalian X chromosome. Annu Rev Genomics Hum Genet 2005, 6:69-92.
107. Peters M, Bletsch M, Catapano R, Zhang X, Tully T, Bourtchouladze R RNA interference in hippocampus demonstrates opposing roles for CREB and PP1alpha in contextual and temporal long-term memory. Genes Brain Behav 2009.
108. Davidson BL, Boudreau RL RNA interference: a tool for querying nervous system function and an emerging therapy. Neuron 2007, 53:781-788.